PSYCHOPHARMACOLOGY. Westin Copley Place 10 Huntington Ave., Boston, MA. Course Directors:

Transcription

1 40th Annual PSYCHOPHARMACOLOGY Thursday-Sunday, October 20-23, 2016 Westin Copley Place 10 Huntington Ave., Boston, MA Course Directors: Jerrold F. Rosenbaum, MD Psychiatrist-in-Chief Massachusetts General Hospital Stanley Cobb Professor of Psychiatry Harvard Medical School Maurizio Fava, MD Director, Division of Clinical Research of the MGH Research Institute Executive Vice Chair, Department of Psychiatry Executive Director, Clinical Trials Network & Institute (CTNI) Massachusetts General Hospital Associate Dean for Clinical & Translational Research Slater Family Professor of Psychiatry Harvard Medical School

2 WELCOME 40th Annual Psychopharmacology Thursday Sunday October 20-23, 2016 Westin Copley Place 10 Huntington Ave., Boston, MA On behalf of the entire Massachusetts General Hospital Department of Psychiatry, we are proud to welcome you to our 40th Annual Psychopharmacology Conference. We have both been part of this conference in various ways since it began. Now as Course Directors, we reflect and celebrate that over the past 40 years it has educated thousands of professionals on the latest advances in mental health. During each session, we ask our faculty to share their experience in caring for patients of all kinds, from the common to the challenging. Many of the faculty also lead research that molds the standards of care for psychiatric conditions. This perspective as clinician-researchers is unique. That s why our focus at this conference is more than to simply share knowledge. It is to help translate an understanding of evidence into actionable ways you can provide the best possible care to your patients. This year as always, our faculty review the latest data from clinical trials and new studies. They also highlight effective pharmacologic and behavioral interventions for an array of mental health conditions. Specific sessions cover anxiety, ADHD, depression, bipolar disorder, eating disorders, OCD, psychosis, PTSD, substance abuse, and much more. We encourage you to ask questions during Panel Discussions and find answers you need. Also take advantage of Curbside Consultations when faculty can discuss cases face-to-face. And enjoy networking and sharing ideas with more than 700 colleagues who join us this year from nearly all 50 states and 12 countries. Thank you for joining us in Boston this year for our 40th anniversary. And thank you for the trust you place in us. Jerrold F. Rosenbaum, MD Maurizio Fava, MD TARGET AUDIENCE The target audience for this event is psychiatrists, psychologists, general and family practice physicians, psychiatric nurses, physician assistants, nurse practitioners, and social workers. COMPLIMENTARY BREAKFAST AND COFFEE BREAKS Complimentary breakfast and coffee breaks will be available to course participants. Please note that lunch and dinner will be on your own.

3 EVALUATION FORMS/CME/CEU CERTIFICATES Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the Evaluation and CME Information document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows: QUESTIONS Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questions on the index cards provided. Cards will be collected during the last 15 minutes of the lecture prior to the start of the panel discussion. Experience has shown that this method is preferable to that of spontaneous questions. COPYRIGHT The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation. CELLULAR TELEPHONES & PAGERS During the lectures, we ask that you turn your cell phones and pagers to vibrate or off. We also ask that you do not talk on your cell phones inside the meeting room. Thank you for your cooperation. CONTACT INFORMATION For questions or comments, please contact MGH Psychiatry Academy member services at or mghcme@mgh.harvard.edu. LEARNING OBJECTIVES At the end of this educational activity, participants should be able to: Identify rational, evidence-based pharmacologic and non-pharmacologic therapies for patients with unipolar, bipolar, treatment-resistant, and post-partum depression. Assess obstacles to maintenance of long-term recovery and the liability issues associated with psychopharmacology. Discuss diagnostic and evidenced-based treatment strategies for pediatric onset mood disorders. Compare the neurobiology and evidence-based treatment approaches to addiction, anxiety, schizophrenia, and mood disorders. Review the course and treatment of psychiatric disorders during pregnancy. Recognize psychosocial issues and evidence-based treatment modalities for eating and sleep disorders. Analyze drug interactions and the pharmacotherapy of adult ADHD and geriatric disorders. ACCREDITATION This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians. McLean Hospital designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

4 PSYCHOLOGISTS The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for Continuing Education (CE) credits for psychologists. REGISTERED NURSES This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation. SOCIAL WORKERS This program has been approved for 25.5 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D AMERICAN BOARD OF PSYCHIATRY & NEUROLOGY The American Board of Psychiatry and Neurology has reviewed Psychopharmacology 2016 and has approved this program as part of a comprehensive program, which is mandated by the ABMS as a necessary component of maintenance of certification. Other CE Licenses: Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credits associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credits may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

5 AGENDA THURSDAY, OCTOBER 20, :00 8:00PM Neuromodulation 2016: State of the Art THIS IS A TICKETED EVENT, DINNER SERVED Joan A. Camprodon, MD, PhD, MPH, Darin D. Dougherty, MD, MSc, Michael E. Henry, MD FRIDAY, OCTOBER 21, :00 8:00AM Registration & Continental Breakfast 8:00 8:15AM Welcoming Remarks Maurizio Fava, MD 8:15 8:30AM Introduction and Overview Jerrold F. Rosenbaum, MD MODULE TOPIC MOOD DISORDERS 8:30 9:15AM Bipolar Depression Andrew A. Nierenberg, MD 9:15 10:00AM Bipolar Long Term Management Roy H. Perlis, MD, MSc 10:00 10:15AM Coffee Break 10:15 11:00AM Treatment Resistant Depression Maurizio Fava, MD 11:00 12:00PM Panel Discussion Moderator: Jerrold F. Rosenbaum, MD Panelists: Andrew A. Nierenberg, MD; Roy H. Perlis, MD, MSc; Maurizio Fava, MD 12:00 1:00PM Lunch (on your own) MODULE TOPIC ANXIETY/OCD 1:00 1:45PM OCD Michael A. Jenike, MD 1:45 2:30PM PTSD Naomi M. Simon, MD, MSc 2:30 3:15PM Anxiety Disorders and Treatments Kerry J. Ressler, MD, PhD 3:15 3:30PM Coffee Break 3:30 4:15PM Obsessive-Compulsive Related Disorders Lisa M. Zakhary, MD, PhD

6 4:15 5:15PM Panel Discussion Moderator: Michael A. Jenike, MD Panelists: Kerry J. Ressler, MD, PhD; Lisa M. Zakhary, MD, PhD; Naomi M. Simon, MD, MSc 5:15 6:30PM Dinner (on your own) 6:30 7:30PM Friday Evening Seminars (please pick two): 7:30 8:30PM Seminars will begin at 6:30 PM and will repeat at 7:30 PM. Natural Medications for Psychiatric Disorders David Mischoulon, MD, PhD (Adams/Baltic, 7th Floor) Suicide Theodore A. Stern, MD (St. George A-B, 3rd Floor) The Neurobiology of Addiction A. Eden Evins, MD, MPH (America Ballroom, 4th Floor) Psychopharmacology of Sleep Disorders John W. Winkelman, MD, PhD (Empire, 7th Floor) The Neurobiology of Mood and Psychotic Disorders Daphne J. Holt, MD, PhD (St. George C, 3rd Floor) Cognitive-Behavioral Therapy to Augment Psychopharmalogical Therapy Michael W. Otto, PhD (St. George D, 3rd Floor)

7 SATURDAY, OCTOBER 22, :00 8:00AM Continental Breakfast 8:00 8:15AM Welcoming Remarks David H. Rubin, MD MODULE TOPIC PSYCHOSIS 8:15 9:00AM First-Episode Psychosis and Schizophrenia Oliver Freudenreich, MD, FAPM 9:00 9:45AM Rapid Treatments for Psychiatric Disorders Cristina Cusin, MD 9:45 10:00AM Coffee Break 10:00 10:45AM Management of Side-Effects of Antipsychotics Oliver Freudenreich, MD, FAPM 10:45 11:45AM Panel Discussion Moderator: David H. Rubin, MD Panelists: Oliver Freudenreich, MD, FAPM; Cristina Cusin, MD 11:45 1:00PM Lunch (on your own) MODULE TOPIC NEW THERAPIES: WHAT IS ON THE HORIZON? 1:00 1:45PM Stimulation and/or Surgical Approaches to Psychiatric Illness Darin D. Dougherty, MD, MMSc 1:45 2:30PM New Antipsychotic Drugs: Pills and Needles! Frank Tarazi, MBBS, PhD, MBA 2:30 2:45PM Coffee Break 2:45 3:30PM New Treatments for Depression Dan V. Iosifescu, MD, MMSc 3:30 4:15PM What is New in Addiction? A. Eden Evins, MD, MPH 4:15 5:15PM Panel Discussion Moderator: Darin D. Dougherty, MD, MMSc Panelists: Dan V. Iosifescu, MD, MMSc, A. Eden Evins, MD, MPH, Frank Tarazi, MBBS, PhD, MBA 5:15 6:30PM Dinner (on your own)

8 6:30 7:30PM Saturday Evening Seminars (please pick one): Seminars will begin at 6:30 PM and do not repeat. Geriatrics Feyza E. Marouf, MD (Independence A-B, 4th Floor) Traumatic Brain Injury: A Neuropsychiatric Perspective Kaloyan S. Tanev, MD (America Ballroom, 4th Floor) Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, MD (St. George A-B, 3rd Floor)

9 SUNDAY, OCTOBER 23, :00 7:45AM Continental Breakfast 7:45 8:00AM Welcoming Remarks David H. Rubin, MD Module Topic Addiction 8:00 9:00AM Tobacco and Cocaine A. Eden Evins, MD, MPH 9:00 10:00AM Alcohol and Opiates John A. Renner, MD 10:00 10:15AM Coffee Break MODULE TOPIC WOMEN S HEALTH 10:15 11:15AM Pregnancy Lee S. Cohen, MD 11:15 12:15PM Post-Partum Mood Disorders Marlene P. Freeman, MD 12:15 1:15PM Lunch (on your own) MODULE TOPIC ACROSS THE LIFESPAN 1:15 2:15PM Pediatric Bipolar Disorder and Mood Disorders Janet Wozniak, MD 2:15 3:15PM ADHD Joseph Biederman,MD 3:15 3:30pm Coffee Break 3:30 4:30PM Drug Interactions Jonathan E. Alpert, MD, PhD 4:30PM Adjourn

10 FACULTY Course Directors: Jerrold F. Rosenbaum, MD Psychiatrist-in-Chief, Massachusetts General Hospital, Stanley Cobb Professor of Psychiatry, Harvard Medical School Faculty: Jonathan E. Alpert, MD, PhD Associate Chief of Psychiatry for Clinical Services, Director, Depression Clinical and Research Program, Massachusetts General Hospital, Joyce R. Tedlow Associate Professor of Psychiatry, Harvard Medical School Joseph Biederman, MD Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Director, Bressler Center for Autism Spectrum Disorder, Massachusetts General Hospital, Professor of Psychiatry, Harvard Medical School Joan A. Camprodon, MD, PhD, MPH Director, Transcranial Magnetic Stimulation (TMS) clinical service, Director, Laboratory for Neuropsychiatry and Neuromodulation, Director, Translational Research, Division of Neurotherapeutics, Attending Physician, Division of Behavioral Neurology, Department of Neurology, Attending Physician, Division of Neuropsychiatry, Department of Psychiatry, Massachusetts General Hospital, Assistant Professor of Psychiatry, Harvard Medical School Lee S. Cohen, MD Director, Ammon-Pinizzotto Center for Women s Mental Health, Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital, Edmund and Carroll Carpenter Professor of Psychiatry, Harvard Medical School Cristina Cusin, MD Staff Psychiatrist, Depression Clinical and Research Program, Massachusetts General Hospital, Assistant Professor, Harvard Medical School Darin D. Dougherty, MD, MMSc Director, Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School A. Eden Evins, MD, MPH Director, Center for Addiction Medicine, Massachusetts General Hospital, William Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School Maurizio Fava, MD Director, Division of Clinical Research of the MGH Research Institute, Executive Vice Chair, Department of Psychiatry, Executive Director, Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School Marlene P. Freeman, MD Associate Director, Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School Oliver Freudenreich, MD, FAPM Co-Director, MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School Michael E. Henry, MD Director, Somatic Therapy Medical Director, Bipolar Clinic and Research Program, Massachusetts General Hospital Daphne J. Holt, MD, PhD Co-director, Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Associate Professor, Harvard Medical School Dan V. Iosifescu, MD, MMSc Director, Adult Psychopharmacology Program, Mount Sinai Behavioral Health System, Associate Professor of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai Michael A. Jenike, MD Founder, OCD Clinic, Massachusetts General Hospital, Medical Founder, Massachusetts General Hospital/McLean Hospital OCD Institute, Professor of Psychiatry, Harvard Medical School Feyza E. Marouf, MD Geriatric Psychiatrist, MGH Outpatient Clinic Program, Director, Partners Healthcare Geriatric Psychiatry Fellowship, Instructor in Psychiatry, Harvard Medical School David Mischoulon, MD, PhD Director of Research, Depression Clinical and Research Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School

11 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Endowed Chair in Psychiatry at MGH, Director, Bipolar Clinic and Research Program, Associate Director, Depression Clinical and Research Program, Director, Training and Education, MGH Research Institute, Massachusetts General Hospital, Professor of Psychiatry, Harvard Medical School Michael W. Otto, PhD Professor, Department of Psychological and Brain Sciences, Boston University Roy H. Perlis, MD, MSc Director, Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School John A. Renner, MD Associate Chief of Psychiatry, Boston VA Healthcare System, Consultant, Department of Psychiatry, Massachusetts General Hospital, Professor of Psychiatry, Boston University School of Medicine, President, American Academy of Addiction Psychiatry Kerry J. Ressler, MD, PhD Chief Scientific Officer, James and Patricia Poitras Chair in Psychiatry, Chief, Division of Depression & Anxiety Disorders, McLean Hospital, Professor of Psychiatry, Harvard Medical School David H. Rubin, MD Executive Director, Massachusetts General Hospital Psychiatry Academy, Director of Child and Adolescent Psychiatry Residency Training, Massachusetts General Hospital Theodore A. Stern, MD Chief, Avery D. Weisman Psychiatric Consultation Service, Director, Office for Clinical Careers, Massachusetts General Hospital, Ned H. Cassem Professor of Psychiatry in the field of Psychosomatic Medicine/Consultation, Harvard Medical School Kaloyan S. Tanev, MD Director of Clinical Neuropsychiatry Research, Massachusetts General Hospital, Assistant Professor of Psychiatry, Harvard Medical School Frank Tarazi, MBBS, PhD, MBA Associate Professor of Psychiatry & Neuroscience, Harvard Medical School, Director, Psychiatric Neuroscience Program McLean Hospital John W. Winkelman, MD, PhD Chief, Sleep Disorders Clinical Research Program, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School Janet Wozniak, MD Chair, Quality and Safety, Department of Psychiatry, Director, Child and Adolescent Psychiatry Outpatient Service, Director, Pediatric Bipolar Disorder Clinical and Research Program, Massachusetts General Hospital,Associate Professor of Psychiatry, Harvard Medical School Lisa M. Zakhary, MD, PhD Co-Director of Psychopharmacology, OCD and Related Disorders Program, Director of Psychopharmacology, Excoriation Clinic and Research Unit, Massachusetts General Hospital Naomi M. Simon, MD, MSc Professor of Psychiatry, Harvard Medical School, Director, Center for Anxiety & Traumatic Stress Disorders, Director, Complicated Grief Program, Massachusetts General Hospital, Chief Medical Officer, Home Base, Red Sox Foundation and Massachusetts General Hospital

12 FACULTY DISCLOSURE STATEMENTS FACULTY DISCLOSURE STATEMENTS In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below: Commercial Interest The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit Financial relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Relevant financial relationships ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship. The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients: Speakers: Jerrold F. Rosenbaum, MD Equity Interest: Medavante, PsyBrain (co-founder) Maurizio Fava, MD Advisory Board/Consultant: Abbott Laboratories; Acadia; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; epharmasolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; Indivior; i3 Innovus/Ingenis; Intracellular; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation

13 Sciences, Inc.; Naurex, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; PPD; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC ( formerly Clinical Trials Solutions, LLC); Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi- Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Shenox Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceutical; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; VistaGen Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol- Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories Research Support: Abbott Laboratories; Acadia Pharmaceuticals; Alkermes, Inc.; American Cyanamid;Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; AXSOME Therapeutics; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Cerecor; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM);National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; NeuroRx; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite LLC;PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Takeda Pharmaceuticals;Tal Medical; VistaGen); Wyeth- Ayerst Laboratories Stock/Other Financial Options: Compellis Pharmaceuticals, PsyBrain, Inc. Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven. Jonathan E. Alpert, MD, PhD Speaker s honoraria: American Society of Clinical Psychopharmacology, American Psychiatric Association, Janssen, MGH Psychiatry Academy, Nevada Psychiatric Association, North Shore Medical Center, Psicofarma, Reed Medical Education, University of Louisville Royalties: Belvoir Publishing, Marcel Dekker, Institut la Conference Hippocrate Consultant fees: PamLab LLC, Luye Pharmaceuticals Research support: Abbott Labs, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., Forest Pharmaceuticals, GlaxoSmithKline, J&J Pharmaceuticals, Lichtswer Pharma, Novartis, Organon, PamLab LLC, Pharmavite, Roche Laboratories, Solvay Pharma, Sanofi/Synthelabo, Wyeth-Ayerst

14 Joseph Biederman, MD Research support: The Department of Defense, Food & Drug Administration, Ironshore, Lundbeck, Magceutics Inc., Merck, Neurocentria Inc., PamLab, Pfizer, Shire Pharmaceuticals Inc., SPRITES, Sunovion, Vaya Pharma/Enzymotec, and NIH Consultant: I have a financial interest in Avekshan LLC, a company that develops treatments for attention deficit hyperactivity disorder (ADHD). My interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies Departmental Royalties (from a copyrighted rating scale used for ADHD diagnoses): Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH Lee S. Cohen, MD Research Support for the National Pregnancy Registry for Atypical Antipsychotics: Alkermes Biopharamaceuticals; Bristol-Myers Squibb/Otsuka Pharmaceuticals; Forest/Actavis Pharmaceuticals; Ortho-McNeil Janssen Pharmaceuticals; Sunovion Pharmaceuticals, Inc. Other research support: Cephalon, Inc.; JayMac Pharmaceuticals; National Institute on Aging; National Institutes of Health; National Institute of Mental Health; Takeda/Lundbeck Pharmaceuticals Cristina Cusin, MD Speaking/CME/Consulting: Janssen, AZ Royalty/patent: PCT/US15/56192; Acyliccucurbit[N]uril type molecular containers to treat intoxication and substance abuse Darin D. Dougherty, MD, MMSc Research Support: Medtronic Honoraria: Medtronic A. Eden Evins, MD, MPH Research Support (to institution): Forum Pharmaceuticals, Pfizer Inc. Advisory Board: Reckitt Benckizer Marlene P. Freeman, MD Research Funding (investigator initiated studies): Takeda, JayMac Pharmaceuticals Advisory Boards: Takeda, Sunovion, JDS Therapeutics, SAGE CME/honorarium: GOED newsletter (medical editing) Oliver Freudenreich, MD, FAPM Research grant (for PI): Avanir Honoraria (Consulting): Janssen, BeaconHealth Strategies Honoraria/Royalties for editing/writing: Up-To-Date Royalties for writing: Wolters-Kluwer Honoraria (CME speaker): Global Medical Education Michael E. Henry, MD Salary (Spouse): Roche Pharmaceuticals Research Grant (PI): Forest Pharmaceuticals Dan V. Iosifescu, MD, MMSc Consultant (Honoraria): Axsome, CNS Response, Lundbeck, Sunovion Research Funding (though the Icahn School of Medicine at Mount Sinai): Alkermes, Brainsway David Mischoulon, MD, PhD Research Support: Fisher Wallace, Nordic Naturals, Methylation Sciences, Inc. (MSI), and PharmoRx Therapeutics Royalties: Lippincott Williams & Wilkins for published book Natural Medications for Psychiatric Disorders: Considering the Alternatives

15 Andrew A. Nierenberg, MD Consultant: Abbott Laboratories, Astra Zeneca, Basilea, BrainCells Inc., BristolMyers Squibb, Cephalon, Clintara, Corcept, Eli Lilly & Co., Forest, Genaissance, Genentech, GlaxoSmithKline, Innapharma, Janssen Pharmaceutica, Jazz Pharmaceuticals, Lundbeck, Medavante, Merck, Novartis, PamLabs, PGx Health, Pfizer, Roche, Sepracor, Schering Plough, Shire, Somerset, Sunovion, Takeda, Targacept, Teva Grant Support: AFSP, AHRQ, BristolMyers Squibb, Cederroth, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Eli Lilly, NARSAD, NIMH, PCORI, Pfizer, Shire, Stanley Foundation, Takeda, WyethAyerst Honoraria: ADURS, Brain and Behavior Foundation Colvin Prize, University of :Pisa, University of Wisconsin at Madison, University Texas Southwest at Dallas, Health New England and Harold Grinspoon Charitable Foundation and Eli Lilly and AstraZeneca, American Society for Clinical Psychopharmacology and Zucker Hillside Hospital and Forest and Janssen, Brandeis University, International Society for Bipolar Disorder (Prior to 3 years ago, honoraria from BristolMyersSquibb, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Eli Lilly, Shire, WyethAyerst), No speaker bureaus since 2003 Stock Holder: Appliance Computing, Inc. (MindSite); Brain Cells, Inc., Medavante Patents/Copyright: Joint ownership with MGH for Structured Clinical Interview for MADRS and Clinical Positive Affect Scale Other Income: MBL Publishing for past services as Editor-in-chief of CNS Spectrums; Slack Inc. for services as Associate Editor of Psychiatric Annals; Editorial Board, Mind Mood Memory, Belvior Publications Michael W. Otto, PhD Grant Support: NIMH, NIDA Book Royalties: Oxford University Press, Routledge Roy H. Perlis, MD, MSc Scientific Advisory Boards (Consulting): Genomind, Psybrain, Perfect Health Patents/Royalties: Bracket (formerly Concordant Rater Systems) John A. Renner, MD Stockholder: Johnson & Johnson, General Electric Kerry J. Ressler, MD, PhD Founder: Dr. Ressler is a founding member of Extinction Pharmaceuticals/ Therapade Technologies, which exist to develop D-cycloserine for use to augment the effectiveness of psychotherapy. He has received no equity or income from this relationship within the last 3 years. Patents: D-cycloserine and psychotherapy, targeting PACAP for extinction, targeting tachykinin 2 for prevention of fear, targeting angiotensin to improve extinction of fear. Funding: NIMH, HHMI, NARSAD, Burroughs Wellcome Foundation Naomi M. Simon, MD, MSc Research Grants: American Foundation for Suicide Prevention, Department of Defense, Highland Street Foundation, NIH Equity (Spouse): G Zero, Gatekeeper Theodore A. Stern, MD Salary: Academy of Psychosomatic Medicine (Editor in Chief Psychosomatics) Royalties: Elsevier Honoraria: Psychiatric Annals

16 Frank Tarazi, MBBS, PhD, MBA Research Grants: Shire Pharmaceuticals, Sunovion Phmarmaceuticals, Lundbeck A/S, Allergan, Plc John W. Winkelman, MD, PhD Consultant/Honoraria: Advance Medical, Cambridge University Press, FlexPharma, Merck, UpToDate, Otsuka Research Grant: NIMH 1R01MH095792, Luitpold, NeuroMetrix, UCB Janet Wozniak, MD Royalties (Spouse): Cambridge University Press, UptoDate Consultation fees (Spouse): Advance Medical, FlexPharma, Merck Research support (Spouse): UCB Pharma, NeuroMetrix. All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.

17 PSYCHOPHARMACOLOGY CURBSIDE CONSULTANTS SCHEDULE OCTOBER 20-23, 2016 FACULTY NAME TOPIC DAY AND TIME Andrew A. Nierenberg, MD Bipolar Disorder and Friday, October 21, 9:15am 10:15am Depression John D. Matthews, MD Depression and Inpatient Psychiatry Friday, October 21, 10:00am 11:00am Naomi M. Simon, MD, MSc Anxiety and PTSD Friday, October 21, 3:15pm 4:15pm Theodore A. Stern, MD Consult Psychiatry Friday, October 21, 4:00pm 5:00pm Oliver Freudenreich, MD, FAPM Psychosis Saturday, October 22, 9:00am 10:00am Cristina Cusin, MD Rapid Treatments Saturday, October 22, 9:45am 10:45am A. Eden Evins, MD, MPH Addiction Saturday, October 22, 2:15pm 3:15pm Lee S. Cohen, MD Women s Health Sunday, October 23, 11:15am 12:15pm

18

19

20

21 Three Steps to Claiming your CME Credit

22 How to reset your password Please visit and enter the address that you used to set up your account, and then click Submit. You will receive an with instructions to reset your password. The will also include your username. If you do not receive an within 2-3 minutes, please check your Spam/ Junk Mail folder. After resetting your password, return to the activity, enter your login information, and you will be able to complete the evaluation and claim your credit!